I understand about the spot sales, but forward binding contracts are still a guesstimate going forward until transparency given in Q3 activity, cash flow results, October 2023 at the latest.
Without this information combined with ramp up into production numbers the company still at the mercy of volatility.
And yes I fully aware of recovery in spodumene price, that's very factual, just perplexed at CXO extremely low market cap.
But CXO news flow to date very positive, just a case of waiting for another November Day.
(Highest recorded SP for CXO, 2023 we wait).
Thank you,, Dancing ...
:-))))
Ann: Quarterly Activities and Cashflow Report 31 March 2023, page-26
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CXO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
-0.015(11.5%) |
Mkt cap ! $246.4M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 11.5¢ | $2.271M | 18.39M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 2973036 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 1235619 | 14 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| CXO (ASX) Chart |